These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. Venugopal S; Mascarenhas J; Steensma DP Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878 [TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Gaballa MR; Besa EC Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193 [TBL] [Abstract][Full Text] [Related]
8. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904 [TBL] [Abstract][Full Text] [Related]
9. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631 [TBL] [Abstract][Full Text] [Related]
10. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825 [TBL] [Abstract][Full Text] [Related]
11. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881 [TBL] [Abstract][Full Text] [Related]
12. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? Gorshein E; Weber UM; Gore S Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540 [No Abstract] [Full Text] [Related]
13. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096 [TBL] [Abstract][Full Text] [Related]
14. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes. Voutsadakis IA; Cairoli A Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212 [TBL] [Abstract][Full Text] [Related]
15. Genetic deletions in AML and MDS. Ebert BL Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407 [TBL] [Abstract][Full Text] [Related]
16. Dyserythropoiesis of myelodysplastic syndromes. Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603 [TBL] [Abstract][Full Text] [Related]
17. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche. Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549 [TBL] [Abstract][Full Text] [Related]
19. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. List A; Ebert BL; Fenaux P Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113 [TBL] [Abstract][Full Text] [Related]
20. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Talati C; Sallman D; List A Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]